News about Global Pharma

MOMA Therapeutics and Roche Announce Five-Year Discovery Collaboration

This partnership provides Roche with access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival.

Global Pharma | 09/01/2024 | By Manvi |  554

Novartis Set to Acquire Calypso in Transformative Agreement

Calypso, a spin-out from Merck, is focused on the research and development of monoclonal antibodies for an array of autoimmune indications, with an expertise in IL-15 biology.

Global Pharma | 08/01/2024 | By Manvi |  689

Supriya Lifesciences Receives GMP Certification from ANVISA Brazil

Supriya Lifescience Limited has announced that its manufacturing site in Lote Parshuram has received Good Manufacturing Practice (GMP) certification from the Regulatory Authority of Brazil, ANVISA.

Global Pharma | 08/01/2024 | By Manvi |  924

Geneseeq's CanScan Earns FDA Breakthrough Designation for Advanced Cancer Detection

This cutting-edge technology utilizes low-depth whole-genome sequencing on circulating cell-free DNA, demonstrating an impressive 99 percent specificity in identifying early cancer signals.

Global Pharma | 05/01/2024 | By Manvi |  960

Lupin Gets Tentative Approval from U.S. FDA for Dapagliflozin and Saxagliptin Tablets

Dapagliflozin and Saxagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Global Pharma | 05/01/2024 | By Manvi |  577

Immunexpress Receives FDA Clearance for EDTA Blood-Compatible Cartridges for SeptiCyte RAPID

The inclusion of undiluted EDTA blood as a validated sample type is expected to enhance the utility of SeptiCyte RAPID® in the US clinical setting.

Global Pharma | 05/01/2024 | By Manvi |  637

WuXi XDC Enters into Partnership Agreement with IntoCell

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.

Global Pharma | 04/01/2024 | By Manvi |  836

MediLink Therapeutics and Roche Announces Worldwide Collaboration and License Agreement

MediLink Therapeutics have announced that it has entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumours.

Global Pharma | 04/01/2024 | By Manvi |  263

Glenmark is First to Launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India

Glenmark Pharmaceuticals Ltd. has launched a biosimilar of the popular10,11 anti?diabetic drug, Liraglutide, for the first time in India.

Global Pharma | 04/01/2024 | By Manvi |  657

Renovos Biologics Awarded FDA Breakthrough Device Designation for RENOVITE BMP-2

The breakthrough designation is a recognition of RENOVITE® BMP-2's potential to provide more effective diagnosis and treatment for conditions related to bone regeneration.

Global Pharma | 04/01/2024 | By Manvi |  549